{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:08:48Z","timestamp":1789117728176,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017606","name":"Optimum Patient Care","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017606","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s41030-026-00379-6","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:07:58Z","timestamp":1787926078000},"page":"937-953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-419X","authenticated-orcid":false,"given":"Eileen O.","family":"Dareng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trung N.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Urbanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Finch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Emerath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Kurdyukova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Jison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lila","family":"Bahadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Menzies-Gow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3149-3229","authenticated-orcid":false,"given":"Eileen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6105-3574","authenticated-orcid":false,"given":"Elisabeth H.","family":"Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Perez","family":"de Llano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1769-9826","authenticated-orcid":false,"given":"Benjamin","family":"Emmanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Olinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"379_CR1","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention: 2024 update. https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/05\/GINA-2024-Strategy-Report-24_05_22_WMS.pdf. Accessed 09 Jul 2026."},{"key":"379_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343\u201373. https:\/\/doi.org\/10.1183\/09031936.00202013.","journal-title":"Eur Respir J"},{"key":"379_CR3","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/all.14268","volume":"75","author":"I Agache","year":"2020","unstructured":"Agache I, Song Y, Rocha C, et al. Efficacy and safety of treatment with dupilumab for severe asthma: a systematic review of the EAACI guidelines-recommendations on the use of biologicals in severe asthma. Allergy. 2020;75:1058\u201368. https:\/\/doi.org\/10.1111\/all.14268.","journal-title":"Allergy"},{"key":"379_CR4","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1111\/all.16178","volume":"79","author":"E Denton","year":"2024","unstructured":"Denton E, Hew M, Peters MJ, et al. Real-world biologics response and super-response in the International Severe Asthma Registry cohort. Allergy. 2024;79:2700\u201316. https:\/\/doi.org\/10.1111\/all.16178.","journal-title":"Allergy"},{"key":"379_CR5","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","volume":"210","author":"L Perez-de-Llano","year":"2024","unstructured":"Perez-de-Llano L, Scelo G, Tran TN, et al. Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults. Am J Respir Crit Care Med. 2024;210:869\u201380. https:\/\/doi.org\/10.1164\/rccm.202311-2192OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"379_CR6","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1016\/j.jaip.2023.05.044","volume":"11","author":"W Chen","year":"2023","unstructured":"Chen W, Tran TN, Sadatsafavi M, et al. Impact of initiating biologics in patients with severe asthma on long-term oral corticosteroids or frequent rescue steroids (GLITTER): data from the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2023;11:2732\u201347. https:\/\/doi.org\/10.1016\/j.jaip.2023.05.044.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"379_CR7","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","volume":"160","author":"LG Heaney","year":"2021","unstructured":"Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160:814\u201330. https:\/\/doi.org\/10.1016\/j.chest.2021.04.013.","journal-title":"Chest"},{"key":"379_CR8","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1016\/j.jaip.2021.07.056","volume":"9","author":"M Kerkhof","year":"2021","unstructured":"Kerkhof M, Tran TN, Allehebi R, et al. Asthma phenotyping in primary care: applying the International Severe Asthma Registry eosinophil phenotype algorithm across all asthma severities. J Allergy Clin Immunol Pract. 2021;9:4353\u201370. https:\/\/doi.org\/10.1016\/j.jaip.2021.07.056.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"379_CR9","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3390\/jpm13111594","volume":"13","author":"L Carriera","year":"2023","unstructured":"Carriera L, Fanto M, Martini A, et al. Combination of biological therapy in severe asthma: where we are? J Pers Med. 2023;13:1594. https:\/\/doi.org\/10.3390\/jpm13111594.","journal-title":"J Pers Med"},{"key":"379_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01514","volume":"10","author":"C Pelaia","year":"2019","unstructured":"Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514. https:\/\/doi.org\/10.3389\/fphys.2019.01514.","journal-title":"Front Physiol"},{"key":"379_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/ijms25010182","volume":"25","author":"CY Chen","year":"2024","unstructured":"Chen CY, Wu KH, Guo BC, et al. Personalized medicine in severe asthma: from biomarkers to biologics. Int J Mol Sci. 2024;25:182. https:\/\/doi.org\/10.3390\/ijms25010182.","journal-title":"Int J Mol Sci"},{"key":"379_CR12","unstructured":"European Medicines Agency. Fasenra summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fasenra-epar-product-information_en.pdf. Accessed 09 Jul 2026."},{"key":"379_CR13","unstructured":"US Food and Drug Administration. Fasenra prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761070s021lbl.pdf. Accessed 09 Jul 2026."},{"key":"379_CR14","doi-asserted-by":"publisher","first-page":"11614","DOI":"10.18632\/oncotarget.14595","volume":"8","author":"YL Qu","year":"2017","unstructured":"Qu YL, Liu J, Zhang LX, et al. Asthma and the risk of lung cancer: a meta-analysis. Oncotarget. 2017;8:11614\u201320. https:\/\/doi.org\/10.18632\/oncotarget.14595.","journal-title":"Oncotarget"},{"key":"379_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2020.04.041","volume":"147","author":"A Woo","year":"2021","unstructured":"Woo A, Lee SW, Koh HY, et al. Incidence of cancer after asthma development: 2 independent population-based cohort studies. J Allergy Clin Immunol. 2021;147:135\u201343. https:\/\/doi.org\/10.1016\/j.jaci.2020.04.041.","journal-title":"J Allergy Clin Immunol"},{"key":"379_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000035060","volume":"103","author":"Q Huang","year":"2024","unstructured":"Huang Q, Huang Y, Xu S, et al. Association of asthma and lung cancer risk: a pool of cohort studies and Mendelian randomization analysis. Medicine (Baltimore). 2024;103:e35060. https:\/\/doi.org\/10.1097\/md.0000000000035060.","journal-title":"Medicine (Baltimore)"},{"key":"379_CR17","doi-asserted-by":"publisher","first-page":"11871","DOI":"10.1002\/cam4.5875","volume":"12","author":"Y Guo","year":"2023","unstructured":"Guo Y, Bian J, Chen Z, et al. Cancer incidence after asthma diagnosis: evidence from a large clinical research network in the United States. Cancer Med. 2023;12:11871\u20137. https:\/\/doi.org\/10.1002\/cam4.5875.","journal-title":"Cancer Med"},{"key":"379_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/2326-6066.Cir-13-0196","volume":"2","author":"BP Davis","year":"2014","unstructured":"Davis BP, Rothenberg ME. Eosinophils and cancer. Cancer Immunol Res. 2014;2:1\u20138. https:\/\/doi.org\/10.1158\/2326-6066.Cir-13-0196.","journal-title":"Cancer Immunol Res"},{"key":"379_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40264-020-00926-3","volume":"43","author":"DJ Jackson","year":"2020","unstructured":"Jackson DJ, Korn S, Mathur SK, et al. Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab. Drug Saf. 2020;43:409\u201325. https:\/\/doi.org\/10.1007\/s40264-020-00926-3.","journal-title":"Drug Saf"},{"key":"379_CR20","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1182\/blood-2012-06-330845","volume":"120","author":"EA Jacobsen","year":"2012","unstructured":"Jacobsen EA, Helmers RA, Lee JJ, et al. The expanding role(s) of eosinophils in health and disease. Blood. 2012;120:3882\u201390. https:\/\/doi.org\/10.1182\/blood-2012-06-330845.","journal-title":"Blood"},{"key":"379_CR21","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.leukres.2006.10.017","volume":"31","author":"A Utsunomiya","year":"2007","unstructured":"Utsunomiya A, Ishida T, Inagaki A, et al. Clinical significance of a blood eosinophilia in adult T-cell leukemia\/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor. Leuk Res. 2007;31:915\u201320. https:\/\/doi.org\/10.1016\/j.leukres.2006.10.017.","journal-title":"Leuk Res"},{"key":"379_CR22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2174\/0929867323666160119094313","volume":"23","author":"S Sakkal","year":"2016","unstructured":"Sakkal S, Miller S, Apostolopoulos V, et al. Eosinophils in cancer: favourable or unfavourable? Curr Med Chem. 2016;23:650\u201366. https:\/\/doi.org\/10.2174\/0929867323666160119094313.","journal-title":"Curr Med Chem"},{"key":"379_CR23","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/s0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128\u201341. https:\/\/doi.org\/10.1016\/s0140-6736(16)31322-8.","journal-title":"Lancet"},{"key":"379_CR24","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2147\/jaa.S227170","volume":"12","author":"JM FitzGerald","year":"2019","unstructured":"FitzGerald JM, Bleecker ER, Bourdin A, et al. Two-year integrated efficacy and safety analysis of benralizumab in severe asthma. J Asthma Allergy. 2019;12:401\u201313. https:\/\/doi.org\/10.2147\/jaa.S227170.","journal-title":"J Asthma Allergy"},{"key":"379_CR25","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/s0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115\u201327. https:\/\/doi.org\/10.1016\/s0140-6736(16)31324-1.","journal-title":"Lancet"},{"key":"379_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaci.2021.02.009","volume":"148","author":"WW Busse","year":"2021","unstructured":"Busse WW, Bleecker ER, FitzGerald JM, et al. Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment. J Allergy Clin Immunol. 2021;148:266-71.e2. https:\/\/doi.org\/10.1016\/j.jaci.2021.02.009.","journal-title":"J Allergy Clin Immunol"},{"key":"379_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/s2213-2600(18)30406-5","volume":"7","author":"WW Busse","year":"2019","unstructured":"Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7:46\u201359. https:\/\/doi.org\/10.1016\/s2213-2600(18)30406-5.","journal-title":"Lancet Respir Med"},{"key":"379_CR28","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.jaip.2024.04.033","volume":"12","author":"A Bourdin","year":"2024","unstructured":"Bourdin A, Chupp G, Jackson DJ, et al. MELTEMI and COLUMBA: 5-year comparative safety analysis of benralizumab and mepolizumab. J Allergy Clin Immunol Pract. 2024;12:2074-83.e4. https:\/\/doi.org\/10.1016\/j.jaip.2024.04.033.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"379_CR29","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","volume":"9","author":"S Korn","year":"2021","unstructured":"Korn S, Bourdin A, Chupp G, et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol Pract. 2021;9:4381-92.e4. https:\/\/doi.org\/10.1016\/j.jaip.2021.07.058.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"379_CR30","unstructured":"International Severe Asthma Registry. The registry. 2023. https:\/\/www.isar.opcglobal.org\/about. Accessed 09 Jul 2026."},{"key":"379_CR31","unstructured":"ClinicalTrials.gov. NCT03373045. https:\/\/clinicaltrials.gov\/study\/NCT03373045. Accessed 09 Jul 2026."},{"key":"379_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-020-01065-0","volume":"20","author":"JM FitzGerald","year":"2020","unstructured":"FitzGerald JM, Tran TN, Alacqua M, et al. International severe asthma registry (ISAR): protocol for a global registry. BMC Med Res Methodol. 2020;20:212. https:\/\/doi.org\/10.1186\/s12874-020-01065-0.","journal-title":"BMC Med Res Methodol"},{"key":"379_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/por.S251120","volume":"11","author":"CS Ambrose","year":"2020","unstructured":"Ambrose CS, Chipps BE, Moore WC, et al. The CHRONICLE study of US adults with subspecialist-treated severe asthma: objectives, design, and initial results. Pragmat Obs Res. 2020;11:77\u201390. https:\/\/doi.org\/10.2147\/por.S251120.","journal-title":"Pragmat Obs Res"},{"key":"379_CR34","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jaip.2019.07.038","volume":"8","author":"JC Virchow","year":"2020","unstructured":"Virchow JC, Katial R, Brusselle GG, et al. Safety of reslizumab in uncontrolled asthma with eosinophilia: a pooled analysis from 6 trials. J Allergy Clin Immunol Pract. 2020;8:540-8.e1. https:\/\/doi.org\/10.1016\/j.jaip.2019.07.038.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"379_CR35","doi-asserted-by":"publisher","first-page":"2417184","DOI":"10.1080\/07853890.2024.2417184","volume":"56","author":"I Pavord","year":"2024","unstructured":"Pavord I, Chan R, Brown N, et al. Long-term safety of mepolizumab for up to approximately 10 years in patients with severe asthma: open-label extension study. Ann Med. 2024;56:2417184. https:\/\/doi.org\/10.1080\/07853890.2024.2417184.","journal-title":"Ann Med"},{"key":"379_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jaci.2024.11.005","volume":"155","author":"T Pongdee","year":"2025","unstructured":"Pongdee T, Li JT. Omalizumab safety concerns. J Allergy Clin Immunol. 2025;155:31\u20135. https:\/\/doi.org\/10.1016\/j.jaci.2024.11.005.","journal-title":"J Allergy Clin Immunol"},{"key":"379_CR37","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","volume":"134","author":"A Long","year":"2014","unstructured":"Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134:560-7.e4. https:\/\/doi.org\/10.1016\/j.jaci.2014.02.007.","journal-title":"J Allergy Clin Immunol"},{"key":"379_CR38","doi-asserted-by":"publisher","first-page":"2500139","DOI":"10.1183\/13993003.00139-2025","volume":"66","author":"KS Ma","year":"2025","unstructured":"Ma KS, Brumbaugh B, Saff RR, et al. Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study. Eur Respir J. 2025;66:2500139. https:\/\/doi.org\/10.1183\/13993003.00139-2025.","journal-title":"Eur Respir J"},{"key":"379_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40257-025-00991-3","volume":"27","author":"T Torres","year":"2026","unstructured":"Torres T. Dupilumab and cutaneous T-cell lymphoma: a call for vigilance, not alarm. Am J Clin Dermatol. 2026;27:5\u20137.","journal-title":"Am J Clin Dermatol"},{"key":"379_CR40","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jaci.2024.10.022","volume":"155","author":"J Cabrera-Perez","year":"2025","unstructured":"Cabrera-Perez J. Dupilumab-associated cutaneous T-cell lymphoma progression: a retrospective cohort study and immunotranscriptomic analysis. J Allergy Clin Immunol. 2025;155:536\u201348. https:\/\/doi.org\/10.1016\/j.jaci.2024.10.022.","journal-title":"J Allergy Clin Immunol"},{"key":"379_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250430","volume":"16","author":"L Salameh","year":"2021","unstructured":"Salameh L, Mahboub B, Khamis A, et al. Asthma severity as a contributing factor to cancer incidence: a cohort study. PLoS ONE. 2021;16:e0250430. https:\/\/doi.org\/10.1371\/journal.pone.0250430.","journal-title":"PLoS ONE"},{"key":"379_CR42","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/s41416-022-01718-5","volume":"126","author":"C Delon","year":"2022","unstructured":"Delon C, Brown KF, Payne NWS, et al. Differences in cancer incidence by broad ethnic group in England, 2013\u20132017. Br J Cancer. 2022;126:1765\u201373. https:\/\/doi.org\/10.1038\/s41416-022-01718-5.","journal-title":"Br J Cancer"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00379-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-026-00379-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00379-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:44:13Z","timestamp":1789116253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-026-00379-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["379"],"URL":"https:\/\/doi.org\/10.1007\/s41030-026-00379-6","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eileen O. Dareng, Trung N. Tran, Ryan Finch, Ulrika Emerath, Yulia Kurdyukova, Maria L. Jison, Lila Bahadori, Andrew Menzies-Gow, and Benjamin Emmanuel are employed by AstraZeneca and may own stock or stock options. Lynda Olinger was contracted by AstraZeneca at the time of study. Hannah Urbanski was an employee of AstraZeneca at the time of the study. Eileen Wang has received honoraria from AstraZeneca, GlaxoSmithKline, Amgen, and Genentech. Elisabeth H. Bel has received funding from AstraZeneca. Luis Perez de Llano received grant\/research support from AstraZeneca, Chiesi, Sanofi, Menarini; honoraria for speaker\u2019s bureau from AstraZeneca, GSK, Sanofi, FAES; honoraria for advisory boards from AstraZeneca, Sanofi, GSK, Chiesi, FAES; and non-financial support from AstraZeneca, GSK, Sanofi, GEBRO. Current affiliation details for Elisabeth H. Bel: Department of Medical Decision Making, Leiden University Medical Center, Leiden, Netherlands.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with International Society for Pharmacoepidemiology (ISPE; 2015) Guidelines for Good Epidemiology Practices and applicable regulatory requirements, including European Medicines Agency (EMA) Guideline on Good Pharmacovigilance Practices: Module VIII \u2013 Post-Authorization Safety Studies (EMA, 2016). The individual registries involved in ISAR all received Institutional Review Board (IRB) or Ethics Committee approval for data collection. All data collection sites in ISAR obtained regulatory agreement in compliance with specific data transfer laws, country-specific legislation, and relevant ethical boards and organizations. The ISAR database has ethical approval from the Anonymous Data Ethics Protocols and Transparency (ADEPT) committee (ADEPT0218) and is registered with the European Union Electronic Register of Post-Authorization studies (ENCEPP\/DSPP\/23720). Patients participating in ISAR provided informed consent. The CHRONICLE registry also received IRB approval (Advarra, Columbia, MD, 3 November 2017). Patients participating in CHRONICLE had to provide written informed consent to participate. ISAR is operated by Optimum Patient Care (OPC) and co-funded by OPC and AstraZeneca. As authors from AstraZeneca participated in this study and the study was approved by the ISAR Steering Committee, no additional permissions were needed to access and analyze the data. The CHRONICLE severe asthma registry was sponsored by AstraZeneca; as authors from AstraZeneca participated in this study, no additional permissions were needed to access and analyze the data.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}